DNA methylation in Parkinson's disease
Open accessAbstract
Epigenetic processes control the embryonic development into multicellular organisms and determine the functional differences of genetically identical cells and individuals. They are also involved in a variety of complex functions such as learning and memory consolidation and have been implicated in aging processes. Beyond the actual genetic information encoded in the DNA sequence, epigenetic modifications in particular DNA methylation and various histone modifications shape the chromatin into a transcriptional permissive or repressive state. DNA methylation patterns are altered by environmental conditions and can be carried forward through mitosis and meiosis. Hence, DNA methylation probably mediates complex environment–gene interactions, determines individual disease characteristics, and contributes to effects and side effects of drugs. In addition to classic monogenic epigenetic diseases, i.e., Prader‐Willi and Rett syndrome, recent data point to an epigenetic component also in apparent sporadic neuro‐psychiatric disorders and increasing evidence suggests a role for altered DNA methylation in Parkinson's disease. Epigenetic alterations, DNA methylation in particular, may account for the yet unexplained individual susceptibility and the variability in the course of Parkinson's disease and could provide hints toward the development of novel therapeutic targets. image Parkinson's disease (PD) is conceptualized as a consequence of genetic variants and environment–gene interactions on a background of age‐related changes. Epigenetic modifications have been implicated in aging and can be altered by environment stimuli. The review explores the possibility of an epigenetic component in PD, focusing on DNA methylation. Methylation of α‐synuclein (SNCA) and microtubule‐associated protein tau gene appear to be of particular importance and epigenome‐wide methylation studies point to several additional candidate genes which may contribute to the individual susceptibility toward PD. This article is part of a special issue on Parkinson disease.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The contribution of epigenetic modifications to neurodegenerative diseases such as PD and AD has been addressed in a number of studies.
“Indeed, the contribution of epigenetic modifications to neurodegenerative diseases such as PD (Wüllner et al., 2016) (Park et al., 2015) and AD (Watson et al., 2016), (Phipps et al., 2016) has been addressed in a number of studies.”
From TET2 Regulates the Neuroinflammatory Response in Microglia (2019) · cites this paper as Wüllner et al., 2016
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Finding the missing heritability of complex diseases
Manolio, T. A., Collins, F. S., Cox, N. J., Goldstein, D. B., Hindorff, L. A., Hunter, D. J., McCarthy, M. I., Ramos, E. M., Cardon, L. R., Chakravarti, A., et al. (2009) · Nature · doi:10.1038/nature08494 · Cited by 8,336 · see citing works
DNA methylation landscapes: Provocative insights from epigenomics
Suzuki, M. M., & Bird, A. (2008) · Nature Reviews Genetics · doi:10.1038/nrg2341 · Cited by 3,039 · see citing works
The Nuclear DNA Base 5-Hydroxymethylcytosine Is Present in Purkinje Neurons and the Brain
Kriaucionis, S., & Heintz, N. (2009) · Science · doi:10.1126/science.1169786 · Cited by 2,700 · see citing works
International Parkinson's Disease Genomics Consortium (IPDGC), Nalls, M. A., Parkinson's Study Group (PSG) Parkinson's Research: The Organized GENetics Initiative (PROGENI), 23andMe, GenePD, NeuroGenetics Research Consortium (NGRC), Hussman Institute of Human Genomics (HIHG), Investigator, T. A. J. D., (CHARGE), C. F. H. A. A. R. I. G. E., North American Brain Expression Consortium (NABEC), et al. (2014) · Nature Genetics · doi:10.1038/ng.3043 · Cited by 1,895 · see citing works
Parental olfactory experience influences behavior and neural structure in subsequent generations
Dias, B. G., & Ressler, K. J. (2014) · Nature Neuroscience · doi:10.1038/nn.3594 · Cited by 1,338 · see citing works
Dynamic Readers for 5-(Hydroxy)Methylcytosine and Its Oxidized Derivatives
Spruijt, C. G., Gnerlich, F., Smits, A. H., Pfaffeneder, T., Jansen, P. W. T. C., Bauer, C., Münzel, M., Wagner, M., Müller, M., Khan, F., et al. (2013) · Cell · doi:10.1016/j.cell.2013.02.004 · Cited by 973 · see citing works
Human iPSC-based modeling of late-onset disease via progerin-induced aging
Miller, J. D., Ganat, Y. M., Kishinevsky, S., Bowman, R. L., Liu, B., Tu, E. Y., Mandal, P. K., Vera, E., Shim, J.-W., Kriks, S., et al. (2013) · Cell stem cell · doi:10.1016/j.stem.2013.11.006 · Cited by 777 · see citing works
Mertens, J., Paquola, A. C. M., Ku, M., Hatch, E., Böhnke, L., Ladjevardi, S., McGrath, S., Campbell, B., Lee, H., Herdy, J. R., et al. (2015) · Cell Stem Cell · doi:10.1016/j.stem.2015.09.001 · Cited by 765 · see citing works
Maunakea, A. K., Chepelev, I., Cui, K., & Zhao, K. (2013) · Cell Research · doi:10.1038/cr.2013.110 · Cited by 552 · see citing works
The epigenetics of aging and neurodegeneration
Lardenoije, R., Iatrou, A., Kenis, G., Kompotis, K., Steinbusch, H. W. M., Mastroeni, D., Coleman, P., Lemere, C. A., Hof, P. R., van den Hove, D. L. A., et al. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.05.002 · Cited by 381 · see citing works
Gao, Y., Chen, J., Li, K., Wu, T., Huang, B., Liu, W., Kou, X., Zhang, Y., Huang, H., Jiang, Y., et al. (2013) · Cell Stem Cell · doi:10.1016/j.stem.2013.02.005 · Cited by 362 · see citing works
MECP2 disorders: from the clinic to mice and back
Lombardi, L. M., Baker, S. A., & Zoghbi, H. Y. (2015) · Journal of Clinical Investigation · doi:10.1172/jci78167 · Cited by 221 · see citing works
Blanch, M., Mosquera, J. L., Ansoleaga, B., Ferrer, I., & Barrachina, M. (2016) · The American Journal of Pathology · doi:10.1016/j.ajpath.2015.10.004 · Cited by 192 · see citing works
Flagged first, then by citations
Research works printed but not linked: 4
- Booth M. J., Ost T. W. B., Beraldi D., Bell N. M., Branco M. R., Reik W. and Balasubramanian S. (2013) Oxidative bisulfite sequencing of 5-methylcytosine and 5-hydroxymethylcytosine. Nat. Protoc. 8, 1841-1851. doi:10.1038/nprot.2013.115. · DOI
- Heijmans B. T., Tobi E. W., Stein A. D., Putter H., Blauw G. J., Susser E. S., Slagboom P. E. and Lumey L. H. (2008) Persistent epigenetic differences associated with prenatal exposure to famine in humans. Proc. Natl Acad. Sci. USA 105, 17046-17049.
- Koh K. P., Yabuuchi A., Rao S. et al. , 2011. Tet1 and Tet2 regulate 5- hydroxymethylcytosine production and cell lineage specification in mouse embryonic stem cells. Cell Stem Cell 8, 200-213. doi:10.1016/j.stem.2011.01.008 · DOI · Paper page
- Wirdefeldt K., Adami H. O., Cole P., Trichopoulos D. and Mandel J. (2011) Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur. J. Epidemiol. 1, 51-58.
Cited by
Sorted by citations
TET2 Regulates the Neuroinflammatory Response in Microglia
Carrillo-Jimenez, A., Deniz, Ö., Niklison-Chirou, M. V., Ruiz, R., Bezerra-Salomão, K., Stratoulias, V., Amouroux, R., Yip, P. K., Vilalta, A., Cheray, M., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.09.013 · Cited by 104 · see citing works
- Authors
- Wüllner, U., Kaut, O., deBoni, L., Piston, D., & Schmitt, I.
- Affiliations
- University of Bonn (DE)
- German Center for Neurodegenerative Diseases (DZNE) and Department of Neurology University of Bonn Bonn Germany
- Corresponding author
- Wüllner, Ullrich
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2016-06-10
- Volume
- 139
- Issue
- S1
- Pages
- 108-120
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W2342685421
- Cited by
- 107
- References
- 13
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 14 · 2023: 13 · 2022: 9 · 2021: 16 · 2020: 13 · 2019: 12 · 2018: 5 · 2017: 7 · 2016: 4
- FWCI
- 1.30
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Neurochemistry (publishedVersion)
- PubMed (publishedVersion)
- DZNE Pub (submittedVersion)
- Funders
- EU/EFPIA Innovative Medicines Initiative Joint Undertaking (115568)
- Epigenomics of Common and Age-related Diseases Programme (01KU1403B)
- ParkinsonFonds Deutschland gGmbH
- Deutsche Parkinson Vereinigung (dPV)
- Topics
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nuclear Receptors and Signaling
- Keywords
- DNA methylation, Parkinson's disease, epigenetics, alpha-synuclein, SNCA, tau gene, tau protein, aging, histone modifications, chromatin, therapeutic target
- MeSH terms
- Aging, Animals, Humans, Parkinson Disease, DNA Methylation, Epigenesis, Genetic, Ubiquitin-Protein Ligases, alpha-Synuclein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
